C92.22
Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Atypical Chronic Myeloid Leukemia (aCML) is a rare form of blood cancer characterized by an overproduction of abnormal myeloid cells in the bone marrow and bloodstream. Unlike typical chronic myeloid leukemia (CML), aCML does not involve the BCR/ABL gene mutation, making it one of the BCR/ABL-negative myeloid leukemias. This condition is often challenging to diagnose and treat. When aCML becomes active again after treatment, it is described as being in relapse, requiring careful management and monitoring.
Causes & Symptoms
Clinical Causes: The exact cause of aCML is unknown, but it involves genetic mutations that lead to abnormal growth of myeloid cells. No clear association with environmental or lifestyle factors has been established. In some cases, prior exposure to chemotherapy or radiation therapy may influence the development of related blood disorders. Genetic mutations in certain genes (excluding BCR/ABL) play a role in disease development.
Key Symptoms: Unintentional weight loss Fatigue and weakness Fever or night sweats Enlarged spleen or liver, causing abdominal discomfort Easy bruising or bleeding Frequent infections Bone pain or tenderness Shortness of breath
Diagnostic & Treatment
Diagnosis Path: Complete blood count (CBC): To detect abnormal white blood cell levels and other blood component changes. Blood smears: Microscopic examination of blood cells for characteristic features. Bone marrow biopsy: To assess cellularity and identify abnormal cell populations. Genetic testing: To rule out BCR/ABL mutation; the absence of this gene confirms BCR/ABL-negative status. Molecular studies: To identify other genetic mutations associated with aCML. Imaging studies: To evaluate organ involvement, such as spleen or liver enlargement.
Treatment Protocols: Chemotherapy: To control abnormal cell growth and reduce disease burden. Targeted therapy: Although BCR/ABL inhibitors are not effective, other targeted drugs may be considered based on genetic findings. Hypomethylating agents: Such as azacitidine, to modify gene expression in cancer cells. Stem cell transplantation: The only potential curative option, suitable for eligible patients. Supportive care: Including blood transfusions, antibiotics, and growth factors to manage symptoms and prevent complications.
Clinical Advice & FAQs
Billing Guidance
Is C92.22 a billable ICD-10 code?
Yes, C92.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.22?
Clinical documentation must specify the nature of Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference